User profiles for "author:Mario Mandala"

mario mandala

University of Perugia
Verified email at unipg.it
Cited by 38500

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

S Gandini, D Massi, M Mandalà - Critical reviews in oncology/hematology, 2016 - Elsevier
Background Despite the success of immunotherapy directed at inhibiting of programmed
death-1 (PD-1)/PD-ligand (L) 1 signaling, it is not established whether PD-L1 expression …

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

JS O'Donnell, D Massi, MWL Teng… - Seminars in cancer biology, 2018 - Elsevier
Cancer therapies will increasingly be utilized in combination to treat advanced malignancies
so as to increase their long-term efficacy in a greater proportion of patients. In particular …

Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities

B Merelli, D Massi, L Cattaneo, M Mandalà - Critical reviews in oncology …, 2014 - Elsevier
A dynamic interplay exists between host and tumor, and the ability of the tumor to evade
immune recognition often determines the clinical course of the disease. Significant …

[HTML][HTML] Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

GV Long, A Hauschild, M Santinami… - … England Journal of …, 2017 - Mass Medical Soc
Background Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor
trametinib improved survival in patients with advanced melanoma with BRAF V600 …

[HTML][HTML] Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

J Larkin, PA Ascierto, B Dréno, V Atkinson… - … England Journal of …, 2014 - Mass Medical Soc
Background The combined inhibition of BRAF and MEK is hypothesized to improve clinical
outcomes in patients with melanoma by preventing or delaying the onset of resistance …

[HTML][HTML] Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

J Weber, M Mandala, M Del Vecchio… - … England Journal of …, 2017 - Mass Medical Soc
Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been
approved for the treatment of advanced melanoma. In the United States, ipilimumab has …

[HTML][HTML] Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

GV Long, D Stroyakovskiy, H Gogas… - … England Journal of …, 2014 - Mass Medical Soc
Background Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone,
delays the emergence of resistance and reduces toxic effects in patients who have …

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label …

K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo… - The Lancet, 2018 - thelancet.com
Background Patients with advanced gastric or gastro-oesophageal junction cancer that
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with …

[HTML][HTML] Adjuvant pembrolizumab versus placebo in resected stage III melanoma

AMM Eggermont, CU Blank, M Mandala… - … England Journal of …, 2018 - Mass Medical Soc
Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to
prolong progression-free and overall survival among patients with advanced melanoma. We …

Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical …

CS Fuchs, T Doi, RW Jang, K Muro, T Satoh… - JAMA …, 2018 - jamanetwork.com
Importance Therapeutic options are needed for patients with advanced gastric cancer
whose disease has progressed after 2 or more lines of therapy. Objective To evaluate the …